Form 4 Filing for Faeth Therapeutics, Inc.

On June 22, 2026, STEPHENSON BRIAN C, Chief Financial Officer of Faeth Therapeutics, Inc., acquired 7205 shares of Common Stock through multiple transactions at weighted average prices ranging from $19.58 to $23.28. These transactions were conducted via the Brian Stephenson Revocable Trust, with STEPHENSON BRIAN C as the sole trustee. On June 23, 2026, a total of 9230 additional shares of Common Stock were acquired through multiple transactions, with weighted average prices ranging from $23.62 to $25.57. All shares acquired were through the Brian Stephenson Revocable Trust, with STEPHENSON BRIAN C as the sole trustee. The reporting person disclaims beneficial ownership except to the extent of pecuniary interest.